Latest Biotech News

Eli Lilly’s Mounjaro (tirzepatide) won FDA approval to reduce cardiovascular risk, adding a new label that could extend the blockbuster’s reach in cardiometabolic care. In parallel, Teva agreed to...

A surprise trial failure involving AstraZeneca and Ionis’ Wainua (eplontersen) has put pressure on RNA-targeting “silencer” therapies for TTR cardiomyopathy. Data discussed in connection with the...

Revolution Medicines secured a landmark FDA approval for daraxonrasib (Rasonque), a once-daily oral pan-RAS inhibitor for pancreatic ductal adenocarcinoma. Analysts characterized the regulatory...

Genentech, part of Roche, agreed to pay DualityBio $45 million upfront to develop antibody-drug conjugates built around the company’s DUPAC payload platform, with milestone potential exceeding $1...

At ESC26, CRISPR Therapeutics said it will pursue the highest dose of its lipid-lowering gene editing therapy after presenting mixed durability results from early-stage data around a year after...

NeoGenomics said its RaDar ST MRD assay received expanded coverage from CMS’s MolDX program to add immunotherapy response monitoring for late-stage solid tumors. The tumor-informed test uses...

McKesson agreed to acquire Precision Medicine Group in a deal valued at about $2.25 billion, strengthening its oncology and clinical research services footprint. Precision Medicine Group...

Children’s Hospital Colorado signed a multi-phase agreement with GenXys Health Care Systems to integrate pharmacogenomic data into clinical workflows. The first phase focuses on processing genomic...

A case report in Respirology Case Reports described an initial 1-milligram dose of tarlatamab followed by fatal tumor lysis syndrome in a woman with relapsed small-cell lung cancer. The...

The FDA has approved Revolution Medicines’ daraxonrasib (Rasonque) for advanced pancreatic ductal adenocarcinoma, marking the first approval of a drug specifically targeting a genetic driver in...

Genentech has expanded its ADC ambitions with a major licensing deal centered on DualityBio’s topoisomerase inhibitor payload platform. DualityBio said it will receive $45 million upfront and...

The FDA approved Roivant’s brepocitinib, branded as Lisraya, for dermatomyositis—an oral therapy Roivant’s unit Priovant licensed from Pfizer. The approval provides a new steroid-sparing option...

A high-profile heart drug program involving AstraZeneca and Ionis suffered a surprise failure, according to results discussed around the European Society of Cardiology meeting. The setback affects...

Cellares said it is facing a major financial and operational blow after Bristol Myers Squibb terminated their manufacturing collaboration tied to Breyanzi (lisocabtagene maraleucel). The...

SK Biopharmaceuticals agreed to acquire Biohaven’s opakalim (BHV-7000) epilepsy drug through a deal structured with $400 million at closing and up to $795 million total depending on milestones and...

Roche received FDA clearance expanding the use of its HER2 diagnostic tests tied to Jazz Pharmaceuticals’ Ziihera, extending patient identification beyond earlier approved stomach-cancer...

McKesson signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion in an all-cash transaction, aiming to expand clinical research and biopharma commercialization...

The FDA approval of Roivant’s brepocitinib for dermatomyositis reinforces how the agency’s decisions in rare autoimmune disease are continuing to shape commercial planning for “spoke” programs...

An international Phase 3 trial testing pancreatic digestive enzymes and ursodeoxycholic acid in severely malnourished acutely ill children stopped early after interim analyses indicated neither...

Cytokinetics disclosed full pivotal trial results for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), showing improvements in how patients felt and in exercise capacity. The...